CagriSema (Cagrilintide + Semaglutide)
CagriSema (Cagrilintide + Semaglutide) scored 5.3 / 10 (⚖️ Neutral) on the BioHarmony scale as a Substance → Peptide → Other Peptide.
CagriSema is an investigational once-weekly amylin plus GLP-1 injectable that produced about 22.7% weight loss on-treatment in REDEFINE 1, per Garvey 2025 in NEJM. It is not yet approved and lost a head-to-head to tirzepatide.
What is CagriSema (Cagrilintide + Semaglutide)?
CagriSema is an investigational once-weekly injection that combines two appetite drugs in a single dual-chamber pen: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 drug already sold as Wegovy and Ozempic. The idea is simple. Stack two different fullness signals and you get more weight loss than either alone. In the big Phase 3 obesity trial, people without diabetes lost about 22.7% of their body weight on-treatment over 68 weeks, per Garvey 2025. That is the biggest effect size I have scored in this incretin batch.
So why does it land at Neutral instead of higher? Because the ceiling is real. CagriSema is not approved anywhere. Novo Nordisk filed the obesity application with the FDA at the end of 2025, with a decision expected the following autumn. It also lost a direct head-to-head against tirzepatide, it carries the heaviest gastrointestinal load of the batch, and there is still no cardiovascular outcomes trial. The weight loss is genuine and the dual mechanism is novel. The evidence around durability, heart outcomes, and access just has not caught up yet. That gap is what the score reflects.
This is research framing, not medical advice. CagriSema is not something you can legally get from a pharmacy today, and I have not used it.
Terminology
A few terms decide how you read this report, because the gap between a huge weight number and a finished safety record is exactly where CagriSema sits, and because the trial language hides some important nuance.
- Amylin: A hormone released with insulin that signals fullness and slows the stomach. Cagrilintide is a long-acting copy of it.
- GLP-1: Glucagon-like peptide-1. The gut and brain hormone semaglutide imitates to drive insulin release and satiety.
- Cagrilintide: The amylin half of CagriSema, modified with a fatty acid so it lasts about a week.
- Semaglutide: The GLP-1 half of CagriSema, the same molecule in Wegovy and Ozempic.
- On-treatment estimand: The weight result for people who stayed on the drug and reached maintenance dose. This is the 22.7% headline.
- Treatment policy estimand: The result counting everyone, including dropouts and dose reductions. This was 20.4%, lower because many people did not reach full dose.
- HbA1c: A blood marker of average glucose over about three months. An HbA1c at or below 6.5% signals near-normal control.
- Noninferiority: A trial bar showing a drug is at least as good as a comparator within a margin. CagriSema missed this bar against tirzepatide.
- CVOT: Cardiovascular outcomes trial. The large, long study that proves heart benefit or safety. CagriSema does not have a reported one yet.
How do you take CagriSema (Cagrilintide + Semaglutide)?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Dual-chamber single-use pen delivering cagrilintide and semaglutide together in one shot | 2.4 mg cagrilintide plus 2.4 mg semaglutide once weekly at maintenance | No legitimate real-world dosing exists; the drug is not yet sold |
Protocols
Standard 16-week titration (trial schedule) Clinical
- Dose
- 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg of each
- Frequency
- Once weekly, stepping up every 4 weeks
- Duration
- 16 weeks to reach maintenance, then ongoing
This mirrors the Wegovy ramp. The slow climb is the main lever for keeping gastrointestinal side effects manageable.
Maintenance dose (obesity) Clinical
- Dose
- 2.4 mg cagrilintide plus 2.4 mg semaglutide
- Frequency
- Once weekly
- Duration
- Chronic, as long as weight management continues
The target dose used in REDEFINE 1 and REDEFINE 2. Stopping is expected to be followed by weight regain over months.
Type 2 diabetes use (REDEFINE 2 design) Clinical
- Dose
- Same 16-week ramp to 2.4/2.4 mg
- Frequency
- Once weekly
- Duration
- Chronic
In people with type 2 diabetes the weight effect is smaller but glucose control is strong, with 74% reaching an HbA1c at or below 6.5%.
Reduced-dose fallback (poor tolerators) Mixed
- Dose
- Hold at 1.0 mg or 1.7 mg of each if 2.4 mg is not tolerated
- Frequency
- Once weekly
- Duration
- Chronic
Flexible dosing in the trials meant many people stayed below full dose. Lower doses still produce meaningful loss but less than the headline number.
How this score is calculated →
What are the benefits of CagriSema (Cagrilintide + Semaglutide)?
Upside contribution: 3.11
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 5.0 | 1.250 | |
| Breadth | 15% | 4.2 | 0.630 | |
| Evidence | 25% | 4.4 | 1.100 | |
| Speed | 10% | 3.6 | 0.360 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 3.8 | 0.570 | |
| Total | 4.110 |
Upside Rationale
The upside comes almost entirely from raw potency and the freshness of the human data. CagriSema produced the largest weight loss in this incretin batch, about 22.7% on-treatment, and it did it across two large Phase 3 trials plus a confirming Phase 2, per Garvey 2025. The mechanism is genuinely novel, pairing amylin with GLP-1 instead of the GIP route that tirzepatide uses. The boundary condition is that all of this potency is undercut by durability and access: the effect fades when you stop, and you cannot legally get the drug yet. Efficacy, evidence, and breadth carry the upside. Speed and bioindividuality are moderate. Durability drags hardest.
Efficacy (5.0/5.0): Efficacy is the standout. In REDEFINE 1, people without diabetes lost about 22.7% of body weight on-treatment and 20.4% on the broader estimand at 68 weeks, per Garvey 2025, beating semaglutide alone by roughly 5 to 6 percentage points. The Phase 2 trial in diabetes showed 15.6% loss versus 5.1% for semaglutide, confirming the combination adds real value, per Frias 2023. Responder rates were strong, with 60% losing at least 20% of body weight. This is a transformative-grade effect by any pre-incretin standard. The only thing that keeps it from being the undisputed leader is that tirzepatide edged it in a head-to-head, but the weight loss itself is dramatic and reproducible.
Breadth of Benefits (4.2/5.0): Breadth is solid because CagriSema moves weight and glucose together, and weight loss of this size ripples through many systems. In REDEFINE 2, people with type 2 diabetes saw strong glucose control with 74% reaching an HbA1c at or below 6.5%, per Kahn 2025. Large weight loss typically improves blood pressure, lipids, and fatty liver in this drug class, and appetite circuits quiet down meaningfully. The boundary is that most of these downstream benefits are inferred from the class rather than measured for CagriSema directly. There is no published body composition breakdown, no liver-fat readout, and no fitness data, so breadth scores high but not at the ceiling.
Evidence Quality (4.4/5.0): Evidence quality is genuinely strong for a drug this new. Two large Phase 3 trials are published in NEJM, REDEFINE 1 with 3,417 people and REDEFINE 2 with 1,206, plus a Phase 2 trial and a Phase 1b safety study, per Garvey 2025 and Enebo 2021. The trials are large, randomized, and placebo and active controlled. The mechanism is confirmed at the receptor level in animal work, per Hay 2025. What holds the score back from the top: there is no cardiovascular outcomes trial, no published lean-versus-fat-mass data, and no stop-and-regain study. The data that exists is high quality, but the long-term picture is incomplete.
Speed of Onset (3.6/5.0): Speed is moderate. Appetite suppression starts within the first weeks, but the meaningful weight loss builds slowly because the dose climbs over a 16-week ramp, per Garvey 2025. The main weight result was measured at 68 weeks, and the loss kept accruing across most of that window without a clear plateau. This is a slow, durable-feeling climb rather than a fast hit. The early appetite change is quick, which lifts the score, but anyone expecting rapid scale movement in month one should reset expectations toward a multi-month curve.
Durability (2.0/5.0): Durability is the weakest upside dimension and the reason a powerful drug lands at Neutral. No CagriSema-specific stop-and-regain trial has been published, and there is no mechanistic reason to expect it to behave differently from the rest of the class, per Kahn 2025. For GLP-1 drugs, most of the lost weight tends to come back within six to twelve months of stopping, as obesity setpoint physiology reasserts. Amylin agonism is also pharmacologically dependent, meaning the signal stops when the drug stops. This is a maintain-to-keep-it tool, not a one-time reset.
Bioindividuality Upside (3.8/5.0): Response varies in ways that matter. In REDEFINE 1, only 57% of people reached the full 2.4/2.4 mg dose, which means tolerance to the ramp is itself a major source of variation, per Garvey 2025. People with type 2 diabetes lost less weight than those without, around 13.7% versus 20.4%, since diabetes blunts the response, per Kahn 2025. The amylin pathway is a second lever, so people who tolerate the gastrointestinal load and reach full dose tend to do very well, while poor tolerators stall at lower doses with smaller results. Predictable modifiers exist, which lifts this dimension above average.
What are the risks & downsides of CagriSema (Cagrilintide + Semaglutide)?
Downside contribution: 2.84 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 4.0 | 1.200 | |
| Side effects | 15% | 3.4 | 0.510 | |
| Cost | 5% | 3.2 | 0.160 | |
| Effort | 5% | 3.0 | 0.150 | |
| Opportunity | 5% | 2.3 | 0.115 | |
| Dependency | 15% | 3.5 | 0.525 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 3.110 | |||
| Harm subtotal × 1.4 | 3.759 | |||
| Opportunity subtotal × 1.0 | 0.425 | |||
| Combined downside | 4.184 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.844 |
Downside Rationale
The downside is dominated by three things: a real class safety profile, the heaviest gastrointestinal burden in this batch, and the fact that you cannot legally get the drug yet. CagriSema carries the same class warnings as semaglutide, pancreatitis and rodent thyroid signals, which sets a meaningful safety floor even though catastrophic events are rare. The side effect load is genuinely high, with most people hitting gastrointestinal trouble during the ramp. Opportunity cost and cost itself are moderate, dependency is functional rather than addictive, and reversibility is clean. The harm-weighted dimensions, safety, side effects, and reversibility, drive most of the downside.
Safety Risk (4.0/5.0): Safety sits at the class floor because CagriSema shares semaglutide's intrinsic warnings: a rare pancreatitis signal and rodent thyroid C-cell tumors that carry a class warning, plus gallbladder and biliary risk, per Kahn 2025. These are infrequent but serious, which is why the dimension lands at 4.0 rather than lower. Importantly, this is a floor, not a stack: the very common but non-dangerous gastrointestinal effects belong in the side effect dimension, not here. There is no completed cardiovascular outcomes trial, so long-term heart safety is unconfirmed for this specific combination, per Garvey 2025. The amylin half has not added new safety signals beyond the GLP-1 base in the trials so far.
Side Effect Profile (3.4/5.0): Side effects are heavy and the highest in the incretin batch. In REDEFINE 1, any gastrointestinal event hit 79.6% of people, with nausea at 55%, constipation at 30.7%, and vomiting at 26.1%, per Garvey 2025. Most events were mild to moderate and clustered during the 16-week ramp, easing at maintenance. Discontinuation for side effects ran about 5.9% in obesity and 8.4% in diabetes, per Kahn 2025. The gastric slowing from the amylin half adds to the nausea on top of the GLP-1 base, which is why the load is higher than semaglutide alone.
Financial Cost (3.2/5.0): Cost cannot be pinned down because the drug is not on the market. GLP-1 obesity drugs run several hundred to over a thousand dollars a month without coverage, and CagriSema will likely launch in that range. Until approval there is no legitimate retail channel at all, so any current sourcing is gray-market and unpredictable in both price and quality. The score reflects an expensive, ongoing, indefinite cost typical of the class.
Time/Effort Burden (3.0/5.0): Effort is moderate. CagriSema is one weekly subcutaneous shot from a pre-filled pen, which is simple, but the 16-week titration requires stepping the dose every four weeks and managing nausea along the way. There is no daily logistics load like multi-dose peptides carry, but the ramp demands patience and the gastrointestinal management is real work for many people during the first months.
Opportunity Cost (2.3/5.0): Opportunity cost is moderate and mostly about timing. The most direct alternative, tirzepatide, is already approved and beat CagriSema in a head-to-head, 25.5% versus 23.0%, per the program data in Frias 2023. Someone who needs treatment now has a proven, accessible option that produced more loss. Further out, the triple-agonist retatrutide may push weight loss higher still through a third mechanism. CagriSema's edge is a different second mechanism that might help GIP nonresponders, but that is unproven. Chasing an unapproved drug when stronger options exist is the relevant tradeoff.
Dependency/Withdrawal (3.5/5.0): Dependency is functional, not addictive. CagriSema does not create craving or a withdrawal syndrome, but the benefit depends entirely on continued dosing, per Kahn 2025. Stop the drug and appetite returns and weight comes back over months. This is the same need-to-continue pattern seen across the GLP-1 class, which scores in the functional-dependency range rather than the addiction range. There is no documented physical withdrawal, just the return of the underlying condition.
Reversibility (1.8/5.0): Reversibility is one of the genuine strengths. CagriSema clears cleanly when you stop, with no taper required and no permanent physiological change from the drug itself, per Garvey 2025. Any side effect resolves as the drug washes out over a few weeks. The catch worth naming is behavioral, not pharmacological: stopping reverses the weight benefit too, since the appetite suppression goes with it. But the drug leaves the body cleanly, which is exactly what a low reversibility score captures.
Is CagriSema (Cagrilintide + Semaglutide) worth it?
CagriSema lands at Neutral because it pairs the strongest weight effect in this incretin batch with the weakest set of supporting facts around it. The potency is real: about 22.7% loss on-treatment, a novel amylin plus GLP-1 mechanism, and two solid Phase 3 trials, per Garvey 2025. But it is not approved anywhere, it lost a head-to-head to tirzepatide, it carries the heaviest gastrointestinal load of the batch, and there is no heart-outcomes data. For anyone needing treatment today, the approved and slightly stronger option already exists. CagriSema is worth watching closely, not chasing through gray-market channels.
✅ Best for: People researching the obesity-drug pipeline who want to understand the strongest dual-mechanism injectable on the horizon. Those who specifically want the amylin plus GLP-1 route rather than the GIP-based path, perhaps after a poor response to GIP-based drugs, though that benefit is unproven. Patients with type 2 diabetes interested in a drug that drove 74% to an HbA1c at or below 6.5% in trials, per Kahn 2025. People willing to wait for the expected FDA approval in late 2026 rather than source an unapproved drug. Anyone who can tolerate a slow 16-week ramp and a high early gastrointestinal load.
❌ Avoid if: You have a personal or family history of medullary thyroid carcinoma or MEN 2, since the class carries a thyroid C-cell warning, per Kahn 2025. You have had pancreatitis, active gallbladder disease, or severe gastrointestinal disease. You are pregnant or breastfeeding, with no safety data. You take insulin or sulfonylureas without medical supervision, since hypoglycemia risk rises. You need a treatment now, since CagriSema is not legally available and an approved, slightly stronger option exists. You cannot verify source quality, because every current channel is gray-market with real identity and purity risks.
What is CagriSema (Cagrilintide + Semaglutide) best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Body Composition / Fat Loss: 6.8/10
Score: 6.8/10Body composition is where CagriSema is strongest. In the REDEFINE 1 Phase 3 trial, people without diabetes lost about 22.7% of body weight on-treatment and 20.4% on the broader estimand at 68 weeks, per Garvey 2025. That beats semaglutide alone by roughly 5 to 6 percentage points and lands it among the most potent obesity injectables in development. The score is held below 7 because it is not approved, no body-fat-versus-lean-mass breakdown has been published, and it lost a head-to-head to tirzepatide. Still, the raw weight effect is real and reproducible across two large trials.
Metabolic Health: 5.6/10
Score: 5.6/10Metabolic health gains are strong because CagriSema attacks weight and glucose together. In REDEFINE 2, people with type 2 diabetes saw large improvements and 74% reached an HbA1c at or below 6.5%, per Kahn 2025. The Phase 2 trial showed a 15.6% weight drop with diabetes at 32 weeks, far above semaglutide alone, per Frias 2023. The score sits in the mid-5s rather than higher because there is no long-term metabolic follow-up, no published data on insulin resistance markers beyond glucose, and the whole package is still investigational.
Blood Sugar / Glycemic Control: 5.7/10
Score: 5.7/10Blood sugar control is a clear strength in the diabetic population. REDEFINE 2 reported that 74% of people with type 2 diabetes reached an HbA1c at or below 6.5%, a target that signals near-normal glucose, per Kahn 2025. The GLP-1 half of the molecule drives glucose-dependent insulin release and suppresses glucagon, while the weight loss itself improves insulin sensitivity. The score stays in the high-5s because there is no head-to-head glucose comparison published against tirzepatide, no data yet on durable diabetes remission off the drug, and the product is not approved, so this is trial evidence rather than real-world confirmation.
| Use Case | Score | Summary |
|---|---|---|
| ○ Cardiovascular Primary | 4.5 | Cardiovascular benefit is plausible but unproven for CagriSema specifically. Weight loss of this magnitude usually improves blood pressure and lipids, and the GLP-1 class has positive cardiovascular outcomes data from related drugs. The problem is direct evidence: no completed cardiovascular outcomes trial for CagriSema has been reported as of May 2026, per Garvey 2025. Until a dedicated trial reads out, any heart-protection claim is borrowed from semaglutide rather than measured for this combination. |
Frequently Asked Questions
What is CagriSema and how does it actually work?
CagriSema is a single weekly injection that combines two appetite drugs: cagrilintide, a long-acting amylin analogue, and semaglutide, the GLP-1 drug in Wegovy and Ozempic. The two hit different fullness circuits, so they add up. Semaglutide drives glucose-dependent insulin release and brain satiety, while cagrilintide engages amylin receptors in the brainstem and slows the stomach. Rodent work shows the amylin effect depends on those specific receptors, per Hay 2025, which is why the pairing produces more loss than either alone.
How is CagriSema dosed and how long is the ramp-up?
CagriSema is one subcutaneous shot per week from a dual-chamber pen, climbing over 16 weeks from 0.25 mg of each compound to a maintenance dose of 2.4 mg cagrilintide plus 2.4 mg semaglutide. The slow ramp keeps nausea tolerable and mirrors the Wegovy schedule. The trial design used flexible dosing, and only 57% of people reached the full dose inside the study window, per Garvey 2025. You can inject any day, into the abdomen, thigh, or upper arm, with consistent timing.
How much weight does CagriSema actually cause people to lose?
In the REDEFINE 1 Phase 3 trial, people without diabetes lost about 22.7% of body weight on-treatment and 20.4% on the broader estimand at 68 weeks, per Garvey 2025. That beat semaglutide alone by roughly 5 to 6 percentage points. In people with type 2 diabetes the loss was smaller, around 13.7%, since diabetes blunts the response, per Kahn 2025. It is one of the biggest weight effects in development, just not the largest.
Why did CagriSema disappoint and how did it do against tirzepatide?
The infamous stock drop was about expectations, not a failed trial. Novo Nordisk had guided 25% or more weight loss, and CagriSema delivered 22.7% on-treatment, which met the endpoints but missed the hyped bar, per Garvey 2025. The bigger setback came later: in the REDEFINE 4 head-to-head, CagriSema missed noninferiority to tirzepatide, losing 23.0% versus 25.5%, per the program context in Frias 2023. Tirzepatide simply produced more loss in that comparison.
How bad are the side effects and what is known about long-term safety?
Gastrointestinal effects are the main burden and the highest in this drug class. In REDEFINE 1, any gastrointestinal event hit 79.6% of people, with nausea at 55% and vomiting at 26.1%, mostly during the ramp, per Garvey 2025. Discontinuation for side effects ran about 5.9%. Long-term safety is thin: trials run 68 to 84 weeks and no cardiovascular outcomes trial has reported, per Kahn 2025. The class also carries pancreatitis and rodent thyroid warnings.
Who should not use CagriSema?
Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 should avoid CagriSema, since the GLP-1 class carries a thyroid C-cell warning. People with a history of pancreatitis, active gallbladder disease, severe gastrointestinal disease, pregnancy, or breastfeeding should also avoid it, per the class profile described in Kahn 2025. Combining it with insulin or sulfonylureas raises hypoglycemia risk. Because the drug is not yet approved, gray-market sourcing adds identity and purity risks on top of the medical ones.
How fast does CagriSema work and when do results show?
Appetite suppression usually starts within the first weeks, but meaningful weight loss builds over months as the dose climbs. The trial measured its main weight result at 68 weeks, and people kept losing across most of that window, per Garvey 2025. The 16-week titration means full strength is not reached until roughly four months in. This is a slow, sustained tool, not a quick fix, and the curve had not clearly plateaued by the end of the study.
CagriSema versus tirzepatide: which should I research?
Tirzepatide is the more proven choice today. It is approved, and in the REDEFINE 4 head-to-head it produced more weight loss, 25.5% versus 23.0% for CagriSema, per the program data in Frias 2023. CagriSema uses a different second mechanism, amylin instead of GIP, which might help people who do not respond well to GIP-based drugs, but there is no subgroup data to confirm that yet. For most people researching options now, the approved drug with the larger effect, tirzepatide, is the safer bet.
What could change CagriSema (Cagrilintide + Semaglutide)'s score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The most plausible move is upward at approval, because access is currently the single biggest drag on the score. An expected FDA approval in late 2026 would lift cost and remove the gray-market access penalty, nudging the score into worth-trying territory. A positive cardiovascular outcomes trial would raise evidence and breadth together. The biggest downside risk is a safety signal or a discontinuation trial confirming fast, full weight regain, which would push it back toward caution. Because durability and access are the weak links, news on either of those would move the score most.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| FDA approves CagriSema for obesity | Cost 3.2 to 2.4, Opportunity 2.3 to 2.0 | 5.4 / 10 ⚖️ Neutral |
| A cardiovascular outcomes trial shows clear heart benefit | Breadth 4.2 to 4.6, Evidence 4.4 to 4.7 | 5.5 / 10 ⚖️ Neutral |
| Approval plus positive heart-outcomes data both land | Cost 3.2 to 2.4, Evidence 4.4 to 4.7, Breadth 4.2 to 4.6 | 5.6 / 10 ⚖️ Neutral |
| A stop-and-regain trial confirms fast, full weight regain | Durability 2.0 to 1.5, Dependency 3.5 to 4.0 | 5.1 / 10 ⚖️ Neutral |
| A new safety signal emerges in larger or longer use | Safety 4.0 to 4.5, Evidence 4.4 to 4.0 | 5.0 / 10 ⚖️ Neutral |
| Body composition data shows heavy lean-mass loss | Breadth 4.2 to 3.6, Side effects 3.4 to 3.8 | 5.1 / 10 ⚖️ Neutral |
Key Evidence Sources
- Garvey 2025, N Engl J Med: REDEFINE 1, the Phase 3 obesity-without-diabetes trial of CagriSema, reported about 22.7% weight loss on-treatment at 68 weeks.. Primary Phase 3 efficacy trial (REDEFINE 1), 68-week weight loss in obesity without type 2 diabetes, n=3417.
- Garvey 2025, N Engl J Med (DOI): REDEFINE 1 full report of cagrilintide plus semaglutide in obesity.. DOI mirror of the REDEFINE 1 randomized controlled trial published in NEJM, June 2025.
- Kahn 2025, N Engl J Med: REDEFINE 2, the Phase 3 trial of CagriSema in type 2 diabetes, reported strong glucose control with 74% reaching HbA1c at or below 6.5%.. Primary Phase 3 trial (REDEFINE 2) in type 2 diabetes, 68-week weight and glucose endpoints, n=1206.
- Kahn 2025, N Engl J Med (DOI): REDEFINE 2 full report of cagrilintide plus semaglutide in type 2 diabetes.. DOI mirror of the REDEFINE 2 randomized controlled trial in type 2 diabetes, NEJM 2025.
- Frias 2023, Lancet: Phase 2 trial of cagrilintide plus semaglutide in type 2 diabetes showed 15.6% weight loss at 32 weeks versus 5.1% for semaglutide alone.. Phase 2 randomized trial establishing additive weight loss for the combination, 32-week data.
- Hay 2025, eBioMedicine: rodent knockout study showing cagrilintide's weight effect depends on the AMY1R and AMY3R amylin receptors.. Mechanistic study confirming amylin-receptor dependence of the cagrilintide component, parent compound mechanistic context.
- Enebo 2021, Lancet: Phase 1b trial of cagrilintide co-administered with semaglutide established the safety and tolerability of the combination concept in humans.. First human Phase 1b combination study, safety and tolerability groundwork for the program.
- Garvey 2025, N Engl J Med: coadministered cagrilintide and semaglutide in adults with overweight or obesity, gastrointestinal safety detail showing any GI event in 79.6% of participants.. REDEFINE 1 safety subset: coadministered cagrilintide and semaglutide in adults with overweight or obesity, GI event rate 79.6% and discontinuation during the 16-week titration.
What does the evidence say about CagriSema (Cagrilintide + Semaglutide)?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Garvey 2025, Kahn 2025, Frias 2023, Hay 2025, Enebo 2021
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- HbA1c Pre | Expected Watch During | Expected Down
- Fasting Glucose During | Expected Down Pre | Expected Watch
Pulse Dimensions to Watch
- Body During | Expected Watch | Primary
- Energy During | Expected Watch | Secondary
- Drive During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Nausea or vomiting after the weekly shot Scale 1-5 | During | Expected Watch
- Appetite suppression and early fullness at meals Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Severe, persistent abdominal pain radiating to the back (possible pancreatitis): stop and seek care.
- A neck lump, hoarseness, or trouble swallowing (possible thyroid signal): stop and consult a clinician.
- Vomiting or diarrhea bad enough to cause dehydration: pause dosing and rehydrate, get medical help if it persists.
- Personal or family history of medullary thyroid carcinoma or MEN 2: do not use, the class carries a thyroid C-cell warning.
- Active gallbladder disease or signs of gallstones: consult a clinician before continuing.
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.110 − 2.844 = 0.266
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (0.266 / 5) × 5 = 5.3 / 10
